Study identifies mechanism that impedes the effectiveness of melanoma therapies

FHS
June 27, 2024
4:46 pm

In many cases of malignant melanoma, the effect of targeted treatment is lost over time. A research team from UZH and USZ has now discovered that a factor secreted by tumor cells is responsible for the resistance.

Vosoritide’s first phase 2 study shows increased growth in children with hypochondroplasia

Vosoritide’s first global phase 2 study showed an average increased growth rate of 1.8 cm per year in children with hypochondroplasia, a genetic cause of

April 13, 2024

FDA pushes cancer drug developers to include overall survival data more frequently

For years, the FDA has allowed progression-free survival to serve as both a primary and surrogate endpoint to support speedy new cancer drug approvals. But

November 1, 2023

SwRI and UTSA develop breath analysis techniques to detect TBI

Researchers from Southwest Research Institute (SwRI) and The University of Texas at San Antonio (UTSA) are developing techniques to detect traumatic brain injury (TBI) by

September 26, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.